Diagnostics, Prognostic and Therapeutic Exploitation of Telomeres and Telomerase in Leukemias
Telomeres are specialized structures at the end of human chromosomes. Telomere length decreases with eachcell division, thus, reflecting the mitotic history of somatic cells. Telomerase, the ribonucleoprotein enzyme which main-tains telomeres of eukaryotic chromosomes, is up-regulated in the vast majority of human neoplasia but not in normal so-matic tissues. In contrast to other somatic cells, normal primitive human hematopoietic cells and some peripheral bloodcells expressed low levels of telomerase activity. This activity is thought to play an important role in self-renewal of he-matopoietic stem cells. In malignant disorders, telomere lengths are generally shortened and telomerase expression andactivity enhanced with high differences in the levels. Although it is necessary to be cautious in interpreting these data,there are indications that telomere length and telomerase expression and activity can serve as a molecular marker of theclinical progression and prognosis of most leukemias. Approaches that directly target telomerase, telomeres or telomeraseregulatory mechanisms have been developed. Some of these anti-telomerase strategies in combination with conventionaldrugs proved to be promising in some types of leukemias.
No Supplementary Data
No Article Media
Document Type: Research Article
Affiliations: INSERM U685, InstitutUniversitaire d'Hematologie, Hopital Saint-Louis, 1, avenue ClaudeVellefaux, 75475 Paris cedex 10, France.
Publication date: 2006-06-01
More about this publication?
- Current Pharmaceutical Biotechnology aims to cover all the latest and outstanding developments in Pharmaceutical Biotechnology. Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics in both pre-clinical and clinical areas of Pharmaceutical Biotechnology. Current Pharmaceutical Biotechnology is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments.